Eli Lilly has reached a value of $1 trillion, reportedly driven by demand for its weight loss drugs. The company is also investing $3.5 billion in a manufacturing site in Pennsylvania's Lehigh Valley. The growth of the weight management market, which is expected to reach $381.5 billion by 2033, may be a factor in Eli Lilly's valuation, although it is unclear if other companies have also reached the $1 trillion mark.